{
    "clinical_study": {
        "@rank": "134426", 
        "acronym": "OND", 
        "arm_group": {
            "arm_group_label": "STEM CELL", 
            "arm_group_type": "Other", 
            "description": "intra thecal injection of MNC stem cell therapy"
        }, 
        "brief_summary": {
            "textblock": "This is a Single arm, Single centre trial to check the safety and efficacy of bone marrow\n      derived autologous mono nuclear cell(100 millions per dose )clinical trial to be conducted\n      for 36 months  in patients with optic nerve diseases."
        }, 
        "brief_title": "Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Optic Atrophy", 
        "condition_browse": {
            "mesh_term": [
                "Nervous System Diseases", 
                "Optic Atrophy", 
                "Optic Nerve Diseases", 
                "Atrophy"
            ]
        }, 
        "detailed_description": {
            "textblock": "Optic Nerve Diseases: Conditions which produce injury or dysfunction of the second cranial\n      or optic nerve, which is generally considered a component of the central nervous system.\n      Damage to optic nerve fibres may occur at or near their origin in the retina, at the optic\n      disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical\n      manifestations may include decreased visual acuity and contrast sensitivity, impaired color\n      vision, and an afferent papillary defect. primary out put of clinical study is to measures\n      Improvement in visual loss  and improvement in idiopathic intra cranial.This is a Single\n      arm, Single centre trial to check the safety and efficacy of bone marrow derived autologous\n      mono nuclear cell(100 millions per dose )clinical trial to be conducted for 36 months ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient Should suffer from Optic Nerve diseases Like Diabetic Retinopathy, retinal\n             pigmentation\n\n          -  age  in between 18 to 50\n\n          -  Willingness  to undergo Bone Marrow derived autologous cell therapy.\n\n          -  Ability to comprehend the explained protocol and thereafter give an informed consent\n             as well as sign the require Informed consent form(ICF) for the study.\n\n          -  A ability and willingness to regular visit to hospital for protocol and follow up.\n\n        Exclusion Criteria:\n\n          -  Patients with pre - existing or Current systemic disease  such as lung , liver (\n             exception; History of uncomplicated Hepatitis A),gastrointestinal, Cardiac ,\n             Immunodeficiency,(including HIV) Or laboratory Investigation that could cause a\n             neurological defect including Syphilis, clinically relevant polyneuropathy) etc.\n\n          -  History of Life threatening  Allergic or immune- mediated reaction\n\n          -  Haemodynamically Unstable."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01834079", 
            "org_study_id": "00104"
        }, 
        "intervention": {
            "arm_group_label": "STEM CELL", 
            "description": "Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval  of 7  days,Intrathecal/Intravenous .Follow  up will be taken  to three Months or as required", 
            "intervention_name": "STEM CELL THERAPY", 
            "intervention_type": "Biological", 
            "other_name": "Intrathecal transplantation of autologous stem cells"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Optic Atrophy,Stem cell therapy", 
        "lastchanged_date": "April 15, 2013", 
        "location": {
            "contact": {
                "email": "sac2751982@gmail.com", 
                "last_name": "Sachin P Jamadar, D.Ortho", 
                "phone": "8888788880"
            }, 
            "contact_backup": {
                "email": "drsmitabhoyar@rediffmail.com", 
                "last_name": "Smita S Bhoyar, BAMS.PGCR", 
                "phone": "9372620569"
            }, 
            "facility": {
                "address": {
                    "city": "Pune", 
                    "country": "India", 
                    "state": "Maharashtra", 
                    "zip": "4"
                }, 
                "name": "Chaitanya Hospital"
            }, 
            "investigator": {
                "last_name": "ANANT E BAGUL, MS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease.", 
        "overall_contact": {
            "email": "sac2751982@gmail.com", 
            "last_name": "Sachin P Jamadar, D.Ortho", 
            "phone": "+918888788880"
        }, 
        "overall_contact_backup": {
            "email": "drsmitabhoyar@rediff.com", 
            "last_name": "Smita S Bhoyar, B.A.M.S.PGCR", 
            "phone": "9372620569"
        }, 
        "overall_official": {
            "affiliation": "CHAITANYA HOSPITAL", 
            "last_name": "ANANT E BAGUL, M.S", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Reduction in degeneration of the Optic nerve with improvement in vision", 
            "safety_issue": "Yes", 
            "time_frame": "6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01834079"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chaitanya Hospital, Pune", 
            "investigator_full_name": "Dr. Sachin Jamadar", 
            "investigator_title": "CO-Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Increase in Visual Function", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Improvement in idiopathic intra cranial hypertension", 
                "safety_issue": "Yes", 
                "time_frame": "6 Months"
            }
        ], 
        "source": "Chaitanya Hospital, Pune", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chaitanya Hospital, Pune", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}